A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
← catalyst calendarSponsored by Windtree Therapeutics (industry) · WINT — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
20actual
Sites
15
Countries
Argentina, Israel, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-01 | actual | When the study began enrolling |
| Primary completion | 2025-07-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiogenic Shock
Interventions
- Drug: Istaroxime — also filed as PST2744
- Drug: Placebo — also filed as Lactate
Primary outcome
what the primary-completion date above is the date OFSBP AUC 0-6
measured Start of infusion to 6 hours
Permalink · WINT's whole pipeline · Catalyst calendar · Every registered study · What changed